Lenalidomide (CC-5013)

For research use only. Not for use in humans.

目录号：S1029 中文名称：来那度胺

Lenalidomide (CC-5013) Chemical Structure

CAS No. 191732-72-6

Lenalidomide (CC-5013)是一种TNF-α分泌抑制剂，在PBMCs中IC50为13 nM。Lenalidomide (CC-5013) 是 ubiquitin E3 ligase cereblon (CRBN) 的配体，它通过CRBN-CRL4泛素连接酶引起两个淋巴样转录因子IKZF1和IKZF3的选择性泛素化和降解。Lenalidomide 可促进 cleaved caspase-3 的表达、抑制 VEGF 的表达并诱导凋亡。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1557.33	现货
10mg	RMB 573.3	现货
50mg	RMB 1190.39	现货
200mg	RMB 3333.33	现货
500mg	RMB 4681.34	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Lenalidomide (CC-5013)发表文献122篇：

Nat Mater, 2019, 18(8):892-904

PubMed: 31235902 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2017, 31(6):833-843

PubMed: 28552327 ( click the link to review the publication )

Nat Med, 2016, 22(7):735-43

PubMed: 27294876 ( click the link to review the publication )

Nat Med, 2016, 22(7):727-34

PubMed: 27294874 ( click the link to review the publication )

Adv Sci (Weinh), 2021, e2004846

PubMed: 34060252 ( click the link to review the publication )

Sci Adv, 2021, 7(6)eabd6263

PubMed: 33547076 ( click the link to review the publication )

Sci Adv, 2021, 7(23)eabg2697

PubMed: 34088671 ( click the link to review the publication )

Nat Commun, 2021, 12(1):5183

PubMed: 34465776 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2021, 118(17)e2023172118

PubMed: 33893236 ( click the link to review the publication )

Leukemia, 2021, 35(5):1330-1343

PubMed: 33623139 ( click the link to review the publication )

Theranostics, 2021, 11(12):5742-5758

PubMed: 33897879 ( click the link to review the publication )

Cell Rep, 2021, 34(11):108870

PubMed: 33730585 ( click the link to review the publication )

Haematologica, 2021, 10.3324/haematol.2021.278743

PubMed: 34162179 ( click the link to review the publication )

Cell Death Discov, 2021, 7(1):139

PubMed: 34117218 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(18)9964

PubMed: 34576128 ( click the link to review the publication )

Sci China Life Sci, 2021, 10.1007/s11427-020-1860-2

PubMed: 33439458 ( click the link to review the publication )

Biochem Biophys Res Commun, 2021, 560:1-6

PubMed: 33965784 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Methods Mol Biol, 2021, 2365:3-20

PubMed: 34432236 ( click the link to review the publication )

Hemasphere, 2021, 5(7):e602

PubMed: 34136753 ( click the link to review the publication )

Blood Adv, 2021, bloodadvances.2021005400

PubMed: 34587238 ( click the link to review the publication )

Blood Adv, 2021, 5(10):2467-2480

PubMed: 33999145 ( click the link to review the publication )

Blood Adv, 2021, 5(9):2391-2402

PubMed: 33950175 ( click the link to review the publication )
STAR Protoc, 2021, 2(1):100288

PubMed: 33532735 ( click the link to review the publication )

Nat Cell Biol, 2020, 22(5):526-533

PubMed: 32251398 ( click the link to review the publication )

Mol Cell, 2020, 5;77(5):1092-1106 e9

PubMed: 31973889 ( click the link to review the publication )

Nat Commun, 2020, 17;11(1):359

PubMed: 31953384 ( click the link to review the publication )

Cell Chem Biol, 2020, 14;S2451-9456(20)30145-8

PubMed: 32413286 ( click the link to review the publication )

Br J Haematol, 2020, 10.1111/bjh.17173

PubMed: 33216988 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2020, 10.1152/ajplung.00046.2020

PubMed: 33174448 ( click the link to review the publication )

Cancer Genomics Proteomics, 2020, 17(1):77-89

PubMed: 31882553 ( click the link to review the publication )

Blood Adv, 2020, 4(15):3572-3585

PubMed: 32761232 ( click the link to review the publication )

Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )

Haematologica, 2020, 10.3324/haematol.2019.227215

PubMed: 31919082 ( click the link to review the publication )

Oncotarget, 2020, 11(44):3984-3997

PubMed: 33216827 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31182435 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-018-0205-y

PubMed: 30026574 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0525-6

PubMed: 31358854 ( click the link to review the publication )

Theranostics, 2019, 9(2):540-553

PubMed: 30809292 ( click the link to review the publication )

Cancer Lett, 2019, 440-441:1-10

PubMed: 30312729 ( click the link to review the publication )

J Med Chem, 2019, 62(15):7042-7057

PubMed: 31271281 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(12):2258-2269

PubMed: 31413179 ( click the link to review the publication )

Am J Hematol, 2019, 10.1002/ajh.25692

PubMed: 31804723 ( click the link to review the publication )

Int J Oncol, 2019, 55(2):499-512

PubMed: 31268156 ( click the link to review the publication )

J Blood Med, 2019, 10:217-226

PubMed: 31372079 ( click the link to review the publication )

Blood, 2018, 20;132(12):1293-1303

PubMed: 30042095 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(1):120-129

PubMed: 29066507 ( click the link to review the publication )
Adv Healthc Mater, 2018, 7(17):e1800427

PubMed: 29944201 ( click the link to review the publication )

Cancers (Basel), 2018, 10(1)

PubMed: 29346274 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):703

PubMed: 29899325 ( click the link to review the publication )

Front Immunol, 2018, 9:2917

PubMed: 30619281 ( click the link to review the publication )

Oncoimmunology, 2018, 7(4):e1316438

PubMed: 29632711 ( click the link to review the publication )

Mol Oncol, 2018, 12(2):180-195

PubMed: 29130642 ( click the link to review the publication )

J Immunol, 2018,

PubMed: 29531171 ( click the link to review the publication )

Pulm Circ, 2018, 8(4):2045894018800702

PubMed: 30160595 ( click the link to review the publication )

Blood, 2017, 129(10):1308-1319

PubMed: 28082445 ( click the link to review the publication )

Nat Commun, 2017, 8:14091

PubMed: 28345588 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(15):4280-4289

PubMed: 28270494 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(21):6602-6615

PubMed: 28790111 ( click the link to review the publication )

Leukemia, 2017, 31(12):2652-2660

PubMed: 28479592 ( click the link to review the publication )

Cancer Res, 2017, 77(11):2927-2937

PubMed: 28404587 ( click the link to review the publication )

Haematologica, 2017, 102(12):2113-2124

PubMed: 28860344 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):127

PubMed: 28633670 ( click the link to review the publication )

Eur J Cancer, 2017, 83:19-27

PubMed: 28709135 ( click the link to review the publication )

EBioMedicine, 2017, 20:70-78

PubMed: 28529032 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3140

PubMed: 29072705 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2375-2386

PubMed: 28878026 ( click the link to review the publication )

Br J Haematol, 2017, 179(5):756-771

PubMed: 29048129 ( click the link to review the publication )

Br J Haematol, 2017, 178(6):914-926

PubMed: 28643330 ( click the link to review the publication )

J Biol Chem, 2017, 292(9):3683-3691

PubMed: 28087699 ( click the link to review the publication )

PLoS One, 2017, 12(3):e0173507

PubMed: 28264055 ( click the link to review the publication )
Oncol Lett, 2017, 14(3):3243-3248

PubMed: 28927072 ( click the link to review the publication )

Anticancer Drugs, 2017, 28(4):376-383

PubMed: 28301380 ( click the link to review the publication )

Oncotarget, 2017, 8(33):55405-55421

PubMed: 28903429 ( click the link to review the publication )

Oncotarget, 2017, 8(9):14604-14619

PubMed: 28099937 ( click the link to review the publication )

Leukemia, 2016, 30(12):2351-2363

PubMed: 27311934 ( click the link to review the publication )

Cell Death Differ, 2016, 23(7):1175-84

PubMed: 26823144 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 35:52

PubMed: 27009084 ( click the link to review the publication )

Antiviral Res, 2016, 133:130-9

PubMed: 27465366 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 469(2):236-42

PubMed: 26657848 ( click the link to review the publication )

Oncotarget, 2016, 7(47):77326-77341

PubMed: 27764795 ( click the link to review the publication )

Biogerontology, 2016, 17(5-6):907-920

PubMed: 27484416 ( click the link to review the publication )

Oncotarget, 2016, 7(38):62572-62584

PubMed: 27613836 ( click the link to review the publication )

Oncotarget, 2016, 7(25):38180-38190

PubMed: 27224912 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(7):1628-38

PubMed: 25623213 ( click the link to review the publication )

Cell Rep, 2015, 12(4):622-35

PubMed: 26190113 ( click the link to review the publication )

Hematol Oncol, 2015, 10.1002/hon.2200

PubMed: 25784599 ( click the link to review the publication )

J Pharm Biomed Anal, 2015, 107:151-8

PubMed: 25594893 ( click the link to review the publication )

Leuk Lymphoma, 2015, 10.3109/10428194.2015.1037752

PubMed: 25860244 ( click the link to review the publication )

Oncotarget, 2015, 6(42):44254-73

PubMed: 26497551 ( click the link to review the publication )

Nature, 2015, 523(7559):183-188

PubMed: 26131937 ( click the link to review the publication )

Oncotarget, 2015, 6(5):2794-811

PubMed: 25605239 ( click the link to review the publication )

Genet Mol Res, 2015, 14(4):13588-94

PubMed: 26535672 ( click the link to review the publication )

Exp Hematol Oncol, 2015, 4:21

PubMed: 26251761 ( click the link to review the publication )

Blood, 2014, 123(5):706-16

PubMed: 24319254 ( click the link to review the publication )
Leukemia, 2014, 28(2):373-83

PubMed: 23760401 ( click the link to review the publication )

Leukemia, 2014, 28(8):1716-24

PubMed: 24476765 ( click the link to review the publication )

Int J Cancer, 2014, 135(5):1132-41

PubMed: 24474467 ( click the link to review the publication )

Br J Haematol, 2014, 166(4):529-39

PubMed: 24766330 ( click the link to review the publication )

Cancer Immunol Immun, 2014, 63(10):1023-36

PubMed: 24947180 ( click the link to review the publication )

J Cancer, 2014, 4(8):614-25

PubMed: 24155773 ( click the link to review the publication )

Hematol Oncol, 2014, 10.1002/hon.2179

PubMed: 25394177 ( click the link to review the publication )

J Pharm Biomed Anal, 2014, 61:70-7

PubMed: 22196804 ( click the link to review the publication )

PLoS One, 2014, 9(9):e103015

PubMed: 25181509 ( click the link to review the publication )

J Chromatogr B Analyt Technol Biomed Life Sci, 2014, 949-950:63-9

PubMed: 24463402 ( click the link to review the publication )

Clin Exp Pharmacol Physiol, 2014, 41(7):489-501

PubMed: 24739012 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(11):3019-31

PubMed: 23584492 ( click the link to review the publication )

Leukemia, 2013, 27(8):1715-21

PubMed: 23417027 ( click the link to review the publication )

PLoS One, 2013, 8(1):e54595

PubMed: 23355882 ( click the link to review the publication )

Eur J Haematol, 2013, 91(6):504-13

PubMed: 23992230 ( click the link to review the publication )

J Mol Neurosci, 2013, 51(3):950-8

PubMed: 23636891 ( click the link to review the publication )

J Chromatogr B, 2013, 10.1016/j.jchromb.2014.01.001

PubMed: ( click the link to review the publication )

Oncotarget, 2013, 4(9):1438-48

PubMed: 23988457 ( click the link to review the publication )

ScientificWorldJournal, 2013, 2013:208309

PubMed: 24170980 ( click the link to review the publication )

Blood, 2012, 119(9):2074-82

PubMed: 22246035 ( click the link to review the publication )

Oncogene, 2012, 32(36):4231-42

PubMed: 23045269 ( click the link to review the publication )

Br J Haematol, 2012, 157(6):718-31

PubMed: 22533681 ( click the link to review the publication )

J Virol, 2012, 86(17):9351-60

PubMed: 22718823 ( click the link to review the publication )

Obesity , 2012, 20(11):2174-85

PubMed: 22522886 ( click the link to review the publication )
Clin Cancer Res, 2011, 17(10):3259-71

PubMed: 21430070 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(16):5311-21

PubMed: 21724551 ( click the link to review the publication )

产品安全说明书

E3 ligase Ligand抑制剂选择性比较

生物活性

产品描述

靶点

CRBN ^[3] ()	VEGF ^[1] ()	TNF-α ^[1] (PBMCs)
		13 nM

体外研究

CC-5013强诱导IL-2和sIL-2R产量。CC-5013作用于T细胞，诱导CD28的酪氨酸磷酸化，随后下调NF-κB的激活。^[2] Lenalidomide和Pomalidomide作用于表达与Thalidomide结合野生型CRBN的，而不是Thalidomide结合缺陷型CRBN(YW/AA)的HEK293 T细胞，抑制CRBN自体泛素化。KMS12多发性骨髓瘤细胞中，CRBN野生型蛋白而不是CRBN(YW/AA) 突变型蛋白的过表达, 放大Pomalidomide调节的c-myc和IRF4表达降低和p21(WAF-1) 表达增高。H929 多发性骨髓瘤细胞系中长期抗Lenalidomide 的选择性与CRBN降低相关,然而抗Pomalidomide和 Lenalidomide的DF15R多发性骨髓瘤中, 检测不到CRBN蛋白。^[3] Lenalidomide通过下调肿瘤细胞抑制性分子表达而抑制缺陷发生。Lenalidomide防止肿瘤诱导的T细胞裂解功能障碍发生。Lenalidomide 作用于T细胞，抑制慢性淋巴细胞性白血病（CLL）细胞诱导的T细胞肌动蛋白突触功能受损, 且下调CLL抑制配体及其他受体的表达。Lenalidomide 作用于FL, DLBCL, HL, MM, SCC,和 OC，抑制肿瘤诱导的免疫抑制，且作用于所有检测的肿瘤细胞时,下调免疫抑制配体表达。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
LB771-HNC	NF:5OVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3:xOWlEPTB;Mj6xOVA{QCEQvF2=	M3\4flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
L-363	M{jIdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWToOYoxUUN3ME2yMlkzOjF{IN88US=>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
JAR	MoHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUWwRohUUUN3ME2yMlk4ODBzIN88US=>	MmeyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
EoL-1-cell	NVzxVHY2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NV2wXoRtUUN3ME20MlExPTF3IN88US=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
BT-549	NYrwO4RVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{jiXWlEPTB;Nj6yNVg1QSEQvF2=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
SK-NEP-1	NHn0bGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGHiOlNKSzVyPUeuPFk2OTJizszN	NUTrd3MxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
BV-173	M1:5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1v4XmlEPTB;OD62O\|U5PSEQvF2=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
HMV-II	MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVTDTpFOUUN3ME2xNE4xOTd{IN88US=>	M2rSZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
HCC1806	NVfIZ\|VNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGTxTJhKSzVyPUGxMlQ1PjdizszN	NVXBOY02RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
KASUMI-1	NH\YSFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnThTWM2OD1zMT61O\|Eh\|ryP	NFvFS4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
SK-MEL-28	M2nJVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYLJR\|UxRTFzLkm3OlQh\|ryP	Mo\BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
RPMI-8226	Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MkTlTWM2OD1zMj62NlQyKM7:TR?=	NXfCeHBvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
T47D	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4rDZmlEPTB;MUOuNlA6QSEQvF2=	NIe4cVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
HOP-62	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXfJR\|UxRTF\|LkS4JO69VQ>?	M{TITlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
A2058	NVrXXZhQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYLoU4p7UUN3ME2xN{45OTl7IN88US=>	M2DncFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
SW620	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWSwXmFTUUN3ME2xOE4zPDd\|IN88US=>	NX3yT5JuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
LCLC-103H	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIHlSWpKSzVyPUG0MlQ5QTJizszN	M4WxZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
HAL-01	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHKwdXFKSzVyPUG0MlU4QTZizszN	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
PANC-08-13	NX:1c21kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYrJR\|UxRTF2LkmxNFgh\|ryP	NYWzNlF5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
COLO-684	M1e5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3\PPWlEPTB;MUWuN\|k4QSEQvF2=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
DEL	MnXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MV;JR\|UxRTF3LkS5PUDPxE1?	M{f5S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
K5	NGXJ[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUTJR\|UxRTF4LkG0PFYh\|ryP	M4HFVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
SK-MEL-24	M3LCSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mn3JTWM2OD1zNj60OlUzKM7:TR?=	M{DyNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
ACN	NI\6XplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUDJR\|UxRTF4LkWyPVch\|ryP	MoDwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
H9	MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3HUOGlEPTB;MU[uOlI3KM7:TR?=	NXPPbHZNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
EM-2	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHm2cmhKSzVyPUG3MlE1OyEQvF2=	NHHDTXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
HSC-4	NUfTdIE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVPJR\|UxRTF5Lk[2NFEh\|ryP	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
IGROV-1	NU\YV41FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGHiSW9KSzVyPUG3Mlc5OyEQvF2=	M4TVVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
TE-1	M{\JfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVrJR\|UxRTF5Lkm5Olgh\|ryP	MlS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
LN-405	MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2TzeGlEPTB;MUmuPVA4PiEQvF2=	M2TSRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
MSTO-211H	M4TMbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3LMTmlEPTB;MkCuN\|U4OyEQvF2=	NFzUZ3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
MOLT-4	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2TvUmlEPTB;MkCuOVc2QSEQvF2=	MkjnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
RS4-11	M4r0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NH7zTJJKSzVyPUKyMlE2PjNizszN	NWfPXlM4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
ES3	MnPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIr6VYZKSzVyPUKyMlY6PjNizszN	NV7sfI1ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
SBC-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVrHd3BoUUN3ME2yN{45Pjl4IN88US=>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
CTV-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mn7YTWM2OD1{NT6wNVQ6KM7:TR?=	NF7kT5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
HuP-T3	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4nId2lEPTB;MkWuOFAxQSEQvF2=	M13INVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
HCC2218	MknoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWftbZM{UUN3ME2yOU42PDB5IN88US=>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
HDLM-2	M1m0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NY[4NXlSUUN3ME2yPE4zODJ4IN88US=>	MlPyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
ABC-1	M{X0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIS4dmxKSzVyPUK5MlY6PzRizszN	M4PselxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
MV-4-11	M{jXPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3PXdmlEPTB;MkmuO\|MyPyEQvF2=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
WM-115	Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWXJR\|UxRTNyLkOwPVkh\|ryP	MlfaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
SW1990	M33TOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{mzcGlEPTB;M{CuN\|Mh\|ryP	NHvxOlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
HCC70	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mn3OTWM2OD1\|MD63N\|Q3KM7:TR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
KYSE-520	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVXJR\|UxRTNyLki4N\|kh\|ryP	M2f5b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
JEG-3	NFTS[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml63TWM2OD1\|MT6xOlE1KM7:TR?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
C8166	Mm\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWDJR\|UxRTNzLkKyO\|Qh\|ryP	M4HRU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
SK-OV-3	NVKzbXhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnfqTWM2OD1\|MT62O\|U2KM7:TR?=	NVz6NFR1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
NCI-H526	NF25fIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3nje2lEPTB;M{KuOlg{KM7:TR?=	NITTeFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
NKM-1	NYXH[GpmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3;MNGlEPTB;M{KuPVU3QCEQvF2=	M1K4fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
ECC10	M2rM[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MX;JR\|UxRTN2Lke0OFMh\|ryP	NYrodXBqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
A2780	NX7Tflg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkPFTWM2OD1\|NT6zOlAyKM7:TR?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
KY821	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1fJWGlEPTB;M{WuO\|Y5OSEQvF2=	MorPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
MKN1	NYnvSJltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWHSdJZtUUN3ME2zOk4zOTN5IN88US=>	NYDwcllTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
EKVX	M{DST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NEjhUWFKSzVyPUO3MlQzOTJizszN	NUfrZmszRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
EW-16	NHjaOmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MoLiTWM2OD1\|OD6zPFg2KM7:TR?=	NVLFZlloRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
CTB-1	NHzSXFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWjJR\|UxRTN7Lke3PFkh\|ryP	MoDzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
COR-L105	Mon2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mlm4TWM2OD12MD60O\|Q3KM7:TR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
NCI-SNU-5	NYPnbVhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1X1PWlEPTB;NEGuNlA3QSEQvF2=	NHe4e5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
Mewo	NEfJWphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2rReWlEPTB;NEGuPVg4OSEQvF2=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
BCPAP	M1qydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHz3OXlKSzVyPUSzMlc6OTdizszN	NWjTRWt2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
KARPAS-45	M4POdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3;qZWlEPTB;NESuNlc4PiEQvF2=	M3fCWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
NCI-H1693	MmDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXjJR\|UxRTR4Lk[5PFYh\|ryP	NFHCZoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
H-EMC-SS	NVfHTWZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVnsN2lTUUN3ME20PE4{OjJ2IN88US=>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
697	M4e5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlzyTWM2OD13MD6zOVQ2KM7:TR?=	MkLzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
KP-N-YS	MmPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MV\JR\|UxRTV{LkOxOFIh\|ryP	M4i1RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
NCI-H1304	MlzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWLDRnNtUUN3ME21Nk44ODJ2IN88US=>	NEnObWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
NOS-1	MmiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mnj3TWM2OD13Mj64OVU6KM7:TR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
NCI-H2342	M1fKPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYTJR\|UxRTV\|LkC1NFgh\|ryP	NHvSOoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
KYSE-270	NHrtdJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWPJR\|UxRTV\|Lk[zOlQh\|ryP	NXPPTG5RRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
LU-135	NVLQTVV3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MX3JR\|UxRTV3LkG4OVMh\|ryP	MnjHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
OE33	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Moi4TWM2OD13NT64NVgh\|ryP	NEn3RXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
ML-2	M2TXc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mo\GTWM2OD13NT65OFg6KM7:TR?=	M2nq[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
KMOE-2	NHztS2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MlnQTWM2OD13Nj6yPFk{KM7:TR?=	M{nRelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
Daoy	NFHPfo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXvJR\|UxRTV4LkOyNFQh\|ryP	M3TPRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
KNS-62	NYTiWY9sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFfBOnlKSzVyPUW3MlAyPDJizszN	NY\5Z\|RSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
NBsusSR	NV\ESpd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MljLTWM2OD13Nz61O\|A2KM7:TR?=	NFrySGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
UACC-257	MorVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmXvTWM2OD13OD62NlY1KM7:TR?=	NHvNfJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
LU-139	M2m5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYDJR\|UxRTV6LkiyOkDPxE1?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
CAL-85-1	M1Pze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MV7JR\|UxRTV6Lki2OFMh\|ryP	NV7jO5hIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
NCI-H720	M{foXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYG2N2pbUUN3ME21PE45QTR{IN88US=>	NEDCTIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
MLMA	M3XBbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXXJR\|UxRTV7LkC5NUDPxE1?	NF3WOmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
A3-KAW	NXzjVJluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NIroWYNKSzVyPUW5MlI5ODlizszN	M2rhO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
Ramos-2G6-4C10	NXv1VGQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{m1N2lEPTB;NUmuOlI5PyEQvF2=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
A388	NGH1W49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXPJR\|UxRTZyLkS0PUDPxE1?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
LAMA-84	M3Hpcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmruTWM2OD14MD65PVA2KM7:TR?=	NX3STFFURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
GCT	M3fXemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MV;JR\|UxRTZzLkC3PFYh\|ryP	MkHuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
K-562	NV;ZTHNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1;L[mlEPTB;NkGuOVM{OyEQvF2=	MmDHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
NCI-H1666	M1vEdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGDSZ2RKSzVyPU[xMlg4PSEQvF2=	M{X3PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
NCI-H1993	M17WcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3;VRmlEPTB;NkOuOFA1OyEQvF2=	NU\PRVk3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
NCI-H358	NIXSUJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUfJR\|UxRTZ3LkCxNlEh\|ryP	NVTIVnVDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
NB6	NXf3NmxPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYm2RZRVUUN3ME22OU46QDhizszN	M4e5bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
HCE-T	Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlTZTWM2OD14Nz6wO\|k5KM7:TR?=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
DOK	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYLob\|ZtUUN3ME22O{41QTR6IN88US=>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
HT-1376	MoLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2fKWGlEPTB;NkmuPFMyPCEQvF2=	NHTjVFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
NEC8	M4\aS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWnJR\|UxRTdyLkGyOFMh\|ryP	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
G-402	M1LCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXvJR\|UxRTdyLkmzPVUh\|ryP	NVHnOllSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
GR-ST	NYLEVFhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYfoT\|gyUUN3ME23NU4yPzJizszN	NVLOT4RzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
QIMR-WIL	NEjm[WhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NH7FbpRKSzVyPUexMlQ1OzRizszN	NHnCZpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
CHP-212	M4LzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NE\SUYtKSzVyPUexMlk3PSEQvF2=	M1fjUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
KU812	NW\ocFZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NIPiOpVKSzVyPUeyMlk4ODJizszN	M3LETVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
Becker	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NELxVGZKSzVyPUezMlE1QDlizszN	NF[wU2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
ChaGo-K-1	MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1e4SWlEPTB;N{SuO\|Q5PiEQvF2=	M{XmWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
A498	NHLRW\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{PSOmlEPTB;N{SuPVMxQCEQvF2=	NGKzfFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
NCI-H69	NFz1VFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFjaS4JKSzVyPUe1Mlc3PjNizszN	M1X4d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
NCI-H209	NXfXV5VnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUTBcXJRUUN3ME23PE43OTR5IN88US=>	NHrEeHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
CAL-33	M13IWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYDJR\|UxRTd6Lkm5N\|kh\|ryP	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
COLO-680N	M4PPVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MY\JR\|UxRTd7LkGwNFch\|ryP	MkCzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
D-283MED	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmHWTWM2OD15OT64NVIh\|ryP	Mnz3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
ATN-1	NHzKTZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mnu0TWM2OD16MT6xNVg4KM7:TR?=	NWq3NmM5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
NCI-N87	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXu0bW1kUUN3ME24NU44Ojl4IN88US=>	NG\DZXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
MHH-NB-11	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NX30WIpqUUN3ME24NU45QDR7IN88US=>	NWr6WFVyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
HEL	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXnkWYF{UUN3ME24Nk41OTN2IN88US=>	Mlq3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
NB69	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NITXTItKSzVyPUizMlAxOzNizszN	NYPZNpRmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
MPP-89	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1HhZWlEPTB;OEOuNlU4PSEQvF2=	M{XFOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
COLO-829	M2PBSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVHJR\|UxRTh3LkS5NVIh\|ryP	NHvhfFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
ONS-76	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXrNdnUxUUN3ME24OU44QTB6IN88US=>	NF7Md4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
EW-3	NHjMOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NH30RndKSzVyPUi2MlIxOzJizszN	M3\LfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
EW-11	NFGwWXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mk\HTWM2OD16Nj60N\|M3KM7:TR?=	NHLEOGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
SW900	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NETIZplKSzVyPUi3MlIxPTNizszN	NWTNepdERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
MOLT-13	NXPkbZE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXvoPJlRUUN3ME24O{4zOjR\|IN88US=>	MnLLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
HuP-T4	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NILFRnFKSzVyPUmxMlA1ODVizszN	NUHpXHJORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
HCC1419	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGXxZm9KSzVyPUmxMlY{PzRizszN	NEPTelA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
CAL-72	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NH7RUXBKSzVyPUmyMlAzOTlizszN	M4PNbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
Mo-T	NHHmTVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3nUVWlEPTB;OUKuO\|Y6PyEQvF2=	NGPM[Io9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
OC-314	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlTtTWM2OD17Mj64PFIyKM7:TR?=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
BHT-101	M1LjU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFyySlNKSzVyPUmzMlEh\|ryP	NV\H[ZhbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
EW-18	M2TpNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MkjJTWM2OD17Mz64OFYzKM7:TR?=	Mn3YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
TE-12	M2Ozc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NV\NeIhyUUN3ME25OE4{ODV3IN88US=>	NX7QRWpJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
MDA-MB-361	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYjJR\|UxRTl4LkC1NVYh\|ryP	MkjTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
DF15	MlPTSpVv[3Srb36gZZN{[Xl?		M4m3ZlQhcHK\|	MlTFTY5lfWO2aX;uJI9nKEOUTESvR3JDViC3YnnxeYl1cW5ibHnnZZNmNW2nZHnheIVlKGGrb3zvd{Bl\We{YXTheIlwdiCrbjDoeY1idiCGRkG1JINmdGy\|IHX4dJJme3OrbnegdGxQSy2nUFyteIFo\2WmIHHpc4xweyCjZoTldkA1KGi{czDifUBtfW2rbnXzZ4Vv[2ViYnHz[YQh[mW2YT3nZYxi[3Sxc3nkZZNmKGWweont[UBnemGpbXXueIF1cW:wIHPvcZBt\W2nboTheIlwdiCjc4PhfUwhTUN3MDC9JFAvODV\|IN88UU4>	NXPSW\|hCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizOVg2ODdpPkK4N\|U5PTB5PD;hQi=>
DF15	MmS4SpVv[3Srb36gZZN{[Xl?		NHvBdng1KGi{cx?=	NULWTGtmUW6mdXP0bY9vKG:oIHPldoVjdG:wLX3l[IlifGWmIHnrZZJweyCmZXfyZYRifGmxbjDpckBpfW2jbjDESlE2KGOnbHzzJIV5eHKnc4Ppcoch\VCOLYTh[4dm\CCra3Hyc5Mh[W[2ZYKgOEBpenNiYomgcJVucW6xbXX0dolkKGGwYXz5d4l{NCCHQ{WwJF0hOC5yNkeg{txONg>?	NV3hTppYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlU4OjBpPkK4OFI2PzJyPD;hQi=>
DF15	NImwdWZHfW6ldHnvckBie3OjeR?=		M3eyWVQhcHK\|	NIm4WlNKdmS3Y4Tpc44hd2ZiY3Xy[YJtd25vbXXkbYF1\WRiYXnvcI9{KGSnZ4Lh[IF1cW:wIHnuJIh2dWGwIFTGNVUh[2WubIOg[ZhxemW\|c3nu[{BmWExvdHHn[4VlKGGrb3zvd{Bi\nSncjC0JIhzeyCkeTDseY1qdm:vZYTybYMh[W6jbInzbZMtKEWFNUCgQUAxNjB6NzFOwG0v	M{K3PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK1O\|IxLz5{OESyOVczODxxYU6=
T-cells	MWPGeY5kfGmxbjDhd5NigQ>?		M2mxfVIhfG9iMzDkZZl{	M3P6RWlvcGmkaYTpc44hd2ZiSVytNkBxem:mdXP0bY9vKGmwIHj1cYFvKFRiY3XscJMhdWWjc4Xy[YQh[W[2ZYKgNkB1dyB\|IHThfZMh[nliRVzJV2EtKEWFNUCgQUAxNjF3IN88UU4>	NVntXFhLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxOlgxOTlpPkKzNVY5ODF7PD;hQi=>
NAMALWA	NWGzbYV2SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MUW3NkBpenN?	NEDRR2lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7BUWFNX0FiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBcO0ifdHj5cYllcW6nIHnuZ49zeG:{YYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JJNkcW62aXzsZZRqd25iY3;1cpRqdmduIFnDOVAhRSByLkO2JO69VS5?	MkjVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzNkiwNVkoRjJ\|MU[4NFE6RC:jPh?=
CD34+ progenitor cells	M1jIdWZ2dmO2aX;uJIF{e2G7		M4X4PVE1KGSjeYO=	M36xbWRm[3KnYYPlJIlvKGW{eYTodo9q\CCmaX\m[ZJmdnSrYYTpc44hd2ZiQ1SzOEsheHKxZ3XubZRweiClZXzsd{Bnem:vIH35[Yxw\Hm\|cHzhd5Rq[yC\|eX7kdo9u\SCmZXyoOZEqKHCjdHnlcpQh[XO\|ZYPz[YQh[XNiQ1SzOkBmgHC{ZYPzbY9vKGGodHXyJFE1KGSjeYO=	NVrBWpdkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1O\|Y6OjRpPkG3OVc3QTJ2PD;hQi=>
CD34+ progenitor cells	MYPGeY5kfGmxbjDhd5NigQ>?		MXSxOEBl[Xm\|	NFztdHVF\WO{ZXHz[UBqdiCveXXsc4llKGSrZn\ldoVvfGmjdHnvckBw\iCFREO0L{Bxem:pZX7peI9zKGOnbHzzJIZzd21ibYnlcI9lgXOybHHzeIlkKHO7bnTyc41mKGSnbDi1dUkheGG2aXXueEBie3Onc4Pl[EBieyCFREOzJIV5eHKnc4Ppc44h[W[2ZYKgNVQh\GG7cx?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV5NkmyOEc,OTd3N{[5NlQ9N2F-
CD34+ progenitor cells	M2LPTWZ2dmO2aX;uJIF{e2G7		MkPENVQh\GG7cx?=	NX3kRoh2TGWlcnXhd4UhcW5iZYL5eIhzd2mmIHTp[oZmemWwdHnheIlwdiCxZjDDSFM1MyCycn;n[Y5qfG:{IHPlcIx{KG[{b32gcZlmdG:meYPwcIF{fGmlIIP5coRzd22nIHTlcEg2eSlicHH0bYVvfCCjc4Pld5Nm\CCjczDncJlkd3Cqb4LpckBCKGW6cILld5Nqd25iYX\0[ZIhOTRiZHH5dy=>	M2fmd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUe2PVI1Lz5zN{W3OlkzPDxxYU6=
CD34+ progenitor cells	NWXMT41rT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mke1NVQh\GG7cx?=	M1LKbmlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIH;mJGNFOzRtIIDyc4dmdmm2b4KgZ4VtdHNiZoLvcUBugWWub3T5d5Bt[XO2aXOgd5lv\HKxbXWg[IVtMDWzKTDwZZRq\W62IHHmeIVzKDF2IHThfZM>	M1rmXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUe2PVI1Lz5zN{W3OlkzPDxxYU6=
CD34+ progenitor cells	NHviWFNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NH3IWYIyPCCmYYnz	NF\GT4hIem:5dHigbY5pcWKrdHnvckBw\iCFREO0L{Bxem:pZX7peI9zKGOnbHzzJIZzd21ibn;uMYRmdCh3cTmgcZlmdG:meYPwcIF{fGmlIIP5coRzd22nIIDheIlmdnRiYX\0[ZIhOTRiZHH5dy=>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV5NkmyOEc,OTd3N{[5NlQ9N2F-
DF15	Mn7HSpVv[3Srb36gZZN{[Xl?	Moe0NE4yKHSxIEGwJJVO	MUW1JIhzew>?	M{T4[Wlv\HWldHnvckBw\iClZYLlZoxwdi2vZXTpZZRm\CCjaX;sc5Mh\GWpcnHkZZRqd25iaX6gbJVu[W5iRF[xOUBk\WyuczDheEAxNjFidH:gNVAhfU1iYX\0[ZIhPSCqcoOgZpkhcW2vdX7vZoxwfCCjbnHsfZNqew>?	NVK3cYZnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlU4OjBpPkK4OFI2PzJyPD;hQi=>
OPM2	M1PvV2Z2dmO2aX;uJIF{e2G7	M1nWelAvOSC2bzCxNEB2VQ>?	NIjudlU2KGi{cx?=	NF3UXI1KdmS3Y4Tpc44hd2ZiY3Xy[YJtd25vbXXkbYF1\WRiYXnvcI9{KGSnZ4Lh[IF1cW:wIHnuJIh2dWGwIF;QUVIh[2WubIOgZZQhOC5zIITvJFExKHWPIHHmeIVzKDViaILzJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXN?	MnzuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2MkW3NlAoRjJ6NEK1O\|IxRC:jPh?=
DF15	MULGeY5kfGmxbjDhd5NigQ>?	MoLINE4yKHSxIEGwJJVO	NU\2R4JEPSCqcoO=	MoHiTY5lfWO2aX;uJI9nKGOncnXicI9vNW2nZHnheIVlKGmtYYLvd{Bl\We{YXTheIlwdiCrbjDoeY1idiCGRkG1JINmdGy\|IHH0JFAvOSC2bzCxNEB2VSCjZoTldkA2KGi{czDifUBqdW23bn;icI91KGGwYXz5d4l{	NUnOVXpsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlU4OjBpPkK4OFI2PzJyPD;hQi=>
OPM2	M3vRSmZ2dmO2aX;uJIF{e2G7	MoPhNE4yKHSxIEGwJJVO	NFqyWFI2KGi{cx?=	MoXITY5lfWO2aX;uJI9nKGOncnXicI9vNW2nZHnheIVlKGmtYYLvd{Bl\We{YXTheIlwdiCrbjDoeY1idiCRUF2yJINmdGy\|IHH0JFAvOSC2bzCxNEB2VSCjZoTldkA2KGi{czDifUBqdW23bn;icI91KGGwYXz5d4l{	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR{NUeyNEc,Ojh2MkW3NlA9N2F-
EC9706	MoH1RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	Mn;uNVUxKHWpL33M	NYDtflVCPDhiaILz	MULBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEWFOUewOkBk\WyuczDheEAyPTBidXevcWwh[W[2ZYKgOFghcHK\|IHL5JGNEUy16IHHzd4F6	M4LoUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{W3NFY3Lz5{OEe1O\|A3PjxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-IKKβ / IKKβ ; PubMed: 22698399 Cancer Cell Western blot analysis of the indicated proteins following treatment of OCI-Ly10 cells with lenalidomide (10μM) for the indicated times. MDM2 / p-MDM2 / p-p53 / p53 ; PubMed: 22525275 Oncogene (a) Treatment with lenalidomide (Len) increases phosphorylation of ser46 and thr55 of p53. Namalwa cells were treated with lenalidomide at various concentrations for 48 hours, the cell lysates were prepared and analyzed by Western blotting with antibodies to MDM2, phospho-ser46 of p53, phospho-thr55 of p53 and total p53. (b) Treatment with lenalidomide increases phosphorylation of MDM2 at ser166 and ser186. Namalwa cells were treated with lenalidomide at various concentrations for 48 hours, the cell lysates were immunoprecipitated using anti-MDM2 antibody. The samples were separated by SDS PAGE and then Western blotted with either anti-MDM2 or antibodies specific to phospho-ser166, phospho-ser186, total phospho-serine or total phospho-threonine of MDM2 as indicated.	22698399 22525275
Growth inhibition assay	Cell viability; PubMed: 22698399 Cancer Cell Viability (MTS assay) of ABC and GCB DLBCL cell lines treated with lenalidomide for 4 days. Error bars show the standard error of the mean (SEM) of triplicates.	22698399

体内研究

口服处理Lenalidomide，显著抑制bFGF诱导的血管生成，这种作用存在剂量依赖性。Lenalidomide 显著降低血管面积百分数，从对照组的5.16%降低到实验组的2.58（50 mg/kg剂量处理）和 1.69（250 mg/kg 剂量处理）。 Lenalidomide 显著降低全部MVL，从对照组的21.07降低到实验组的8.11（50 mg/kg剂量处理）和1.90（250 mg/kg剂量处理）。^[5]

激酶实验： ^[1]	- 合并 Assay for inhibition of TNF synthesis by human PBMCs: Human PBMCs from normal donors are obtained by Ficoll−Hypaque density centrifugation. Cells (10⁶ cells/mL) are cultured in RPMI supplemented with 10 AB+ serum, 2 mM l-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin. Lenalidomide is dissolved in DMSO at 20 mg/mL; further dilution is done with culture medium. The final DMSO concentration in all assays including the controls is 0.25%. Lenalidomide is added to cells 1 hour prior to the addition of LPS. PBMCs (10⁶ cells/mL) are stimulated with 1 μg/mL of LPS from Salmonella minnesota R595. Cells, in triplicate, are incubated with LPS for 18−20 hours at 37 °C in 5% CO₂. Supernatants are then harvested and assayed for cytokine levels. In some experiments, supernatants are kept frozen at −70 °C until use. Cell viability is assayed by Trypan blue exclusion dye method. The concentration of TNFα in the culture supernatants is determined by ELISA. Lenalidomide is assayed in a minimum of three separate experiments. Percent inhibition is determined as 100 × [1 − (cytokine(experimental)/cytokine(control))].
细胞实验： ^[3]	- 合并 Cell lines: 良性或恶性 B (CLL)细胞, RPMI8226 MM 细胞 Concentrations: 1 μM或5 nM Incubation Time: 24小时 Method: 使用CellTracker Blue CMAC对良性或恶性B (CLL)细胞(2 × 10⁶)进行染色，然后使用2 μg/mL金黄色葡萄球菌超抗原(sAg) (SEA 和 SEB) 在37^oC下进行脉冲处理30分钟。B细胞和等量T细胞(从原代共培养中纯化的)按200 × g转速离心5分钟，然后与CD8⁺ T 细胞在37^oC下温育10分钟，或者与 CD3⁺ T细胞温育20分钟。使用细胞收集器使细胞转移到显微镜载玻片上，然后在室温下和3% 溶于PBS的甲醛混合15分钟。在完全培养基中加入终浓度为1 μM的Lenalidomide。对照组则使用DMSO处理细胞。 (Only for Reference)
动物实验：^[5]	- 合并 Animal Models: 携带HUVECs细胞的成年雄性Sprague–Dawley大鼠 Dosages: 50 mg/kg和250 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	52 mg/mL (200.57 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+40%PEG 300+5%Tween80+ddH2O	10mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Lenalidomide (CC-5013) SDF

分子量	259.26
化学式	C₁₃H₁₃N₃O₃
CAS号	191732-72-6
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04903197	Not yet recruiting	Drug: VAY736\|Drug: lenalidomide	Non-Hodgkin Lymphoma Diffuse Large B Cell Lymphoma	Novartis Pharmaceuticals\|Novartis	September 30 2021	Phase 1
NCT04974216	Not yet recruiting	Drug: Tafasitamab\|Drug: Lenalidomide\|Drug: Rituximab	DLBCL	The Lymphoma Academic Research Organisation	September 15 2021	Phase 2
NCT04669171	Recruiting	Biological: EO2463\|Drug: lenalidomide\|Biological: rituximab	Follicular Lymphoma\|Marginal Zone Lymphoma	Enterome	July 5 2021	Phase 1\|Phase 2
NCT04796857	Recruiting	Drug: PD-1 Antibody\|Drug: Lenalidomide	Non-GCB/ABC Diffuse Large B-Cell Lymphoma\|High-grade B-cell Lymphoma\|Follicular Lymphoma Grade IIIb\|Transformed Lymphoma\|EBV-Positive DLBCL Nos\|ALK-Positive Anaplastic Large Cell Lymphoma	Huiqiang Huang\|Sun Yat-sen University	March 31 2021	Phase 1\|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
What is the formulation for mouse injection(i.p.)?
回答：
This paper has the information you need: http://link.springer.com/article/10.1208/s12248-012-9401-2. Add lenalidomide to the appropriate volume of sterile phosphate-buffered saline (PBS) containing 1% hydrochloric acid (HCl). the pH of this preparation was adjusted to 7.0–7.6 using sodium hydroxide and sterile filtered using a 0.22 μm Steriflip filter.
问题 2：
what is the procedure to resuspend this compound？
回答：
You can resuspend this compund by DMSO, the solubility is about 52 mg/mL (200.57 mM). For in vivo study, you can prepare the working solution with the vehicle of: 30% PEG400/0.5% Tween80/5% propylene glycol for oral administration.

E3 ligase Ligand Inhibitors with Unique Features

FDA批准的TNF-alpha抑制剂

Pomalidomide : Approved by FDA for relapsed and refractory multiple myeloma.
最新的TNF-alpha抑制剂

Necrostatin-1 : Specific RIP1 inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM.
经典的TNF-alpha抑制剂

Thalidomide : A sedative drug, immunomodulatory agent and also is investigated for treating symptoms of many cancers.

研究领域

产品类型

定制您的化合物库

Lenalidomide (CC-5013)

客户使用Selleck生产的Lenalidomide (CC-5013)发表文献122篇：

产品安全说明书

E3 ligase Ligand抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Lenalidomide (CC-5013) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

技术支持

常见问题及建议解决方法

E3 ligase Ligand Inhibitors with Unique Features